Clinical trial
Trastuzumab for 6 Months or 1 Year in Treating Women With Nonmetastatic Breast…
NCT00381901 · National Cancer Institute, France, Other · Completed
Key facts
| NCT number | NCT00381901 |
|---|---|
| Title | Trastuzumab for 6 Months or 1 Year in Treating Women With Nonmetastatic Breast Cancer That Can Be Removed By Surgery |
| Official title | Protocol of Herceptin Adjuvant With Reduced Exposure, a Randomised Comparison of 6 Months vs 12 Months in All Women Receiving Adjuvant Herceptin [PHARE] |
| Lead sponsor | National Cancer Institute, France, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Genetic, Procedure |
| Interventions | trastuzumab, polymorphism analysis, adjuvant therapy |
| Enrollment | 3,400 |
| Start date | May 1, 2006 |
| Primary completion | May 1, 2011 |
| First posted | Sep 28, 2006 |
| Last update posted | May 13, 2011 |
| Countries | France |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: